Annual report pursuant to Section 13 and 15(d)

Goodwill and Other Intangible Assets

v3.3.1.900
Goodwill and Other Intangible Assets
12 Months Ended
Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Intangible Assets Disclosure [Text Block]
oodwill and Other Intangible Assets
 
Goodwill

During the Company's annual impairment testing of goodwill as of December 31, 2015, the Company recognized an impairment loss of $15.7 million within goodwill impairment in the consolidated statement of operations and comprehensive loss. A rollforward of the carrying value of goodwill from continuing operations from January 1, 2014 to December 31, 2015 is as follows:
 
2015
 
January 1,
Additions
Adjustments
Impairments
December 31,
RedPath
$
15,545

$

$
121

$
(15,666
)
$

 
 
 
 
 
 
 
2014
RedPath
$

$
15,545

$

$

$
15,545




Other Intangible Assets
The net carrying value of the identifiable intangible assets as of December 31, 2015 and December 31, 2014 is as follows: 
 
 
 
As of December 31, 2015
 
As of December 31, 2014
 
Life
 
Carrying
 
Carrying
 
(Years)
 
Amount
 
Amount
Diagnostic assets:
 
 
 
 
 
Asuragen acquisition:
 
 
 
 
 
   Thyroid
9
 
$
8,519

 
$
8,519

   Pancreas
7
 
2,882

 
2,882

   Biobank
4
 
1,575

 
1,575

RedPath acquisition:
 
 
 
 
 
Pancreas test
7
 
16,141

 
16,141

Barrett's test
9
 
18,351

 
18,351

Total
 
 
$
47,468

 
$
47,468

Diagnostic lab:
 
 
 
 
 
CLIA Lab
2.3
 
$
609

 
$
609

 
 
 
 
 
 
Accumulated Amortization
 
 
$
(4,585
)
 
$
(773
)
 
 
 
 
 
 
Net Carrying Value
 
 
$
43,492

 
$
47,304



Amortization expense was $3.8 million for the year ended December 31, 2015 and $0.8 million for the year ended December 31, 2014. Amortization of the thyroid diagnostic asset will begin upon launch of the product. Estimated amortization expense for the next five years is as follows:

2016
2017
2018
2019
2020
$
4,889

$
6,097

$
5,949

$
5,703

$
5,703